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the threshold for a MID also increases by this factor constantly. And this leads to
logarithmic function for quantifying outcomes. We examined a logarithmic func-
tional form for MIDs in nine pairs, a combination of three health states extracted
from EuroQol-5D (State A (21222), B (21122), and C (22222)) and three survival du-
rations (10, 20, and 30 years). An online survey was conducted and 100 subjects
were recruited. . One-way repeated measure analysis of variance and one-way
within subjects analysis were applied. RESULTS: A total of 98 subjects completed
the survey. In State A, the normalized mean of 10, 20, and 30 years were 0.63, 0.61,
and 0.59, respectively. There were no significant difference in the means (p 
0.1102). For State B, the normalized means were 0.66, 0.68, and 0.66 for 10, 20, and
30 years, respectively, with no significant difference among three durations (p 
0.6496). Lastly, in State C, the normalized means for the starting years were 0.57,
0.55, and 0.57, respectively, and there was no statistical difference (p  0.5404).
Thus, the impact of changing durations was not significant in all three states.
CONCLUSIONS: Our findings implies that the MID is constant over proportional
change in duration, indicating that the utility function of the MID follows a loga-
rithmic function. This violation of the normative decisionmodel implies treatment
decisions based on the MID may not represent our preferences for health.
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OBJECTIVES: Budget impact analyses (BIA) are important tools for assessing finan-
cial costs associated with the implementation of health care interventions. As
pressure on the limited budgets of health care systems increases, the role of BIA in
the reimbursement decision-making process is set to rise. Indeed, evidence sug-
gests that in recent years BIA conducted for new healthcare interventions have
increasingly informed reimbursement decisions of payers. The aim of this study
was to investigate any temporal and regional trends in the rate of study publica-
tions reporting the results of a BIA over the last ten years. METHODS: PubMed
searches were performed to identify publications discussing the budget impact of
treatments published for the years 2001, 2005, 2006 and 2010. For each year, the
number of publications including a BIA was calculated as a proportion of all pub-
lications for that year. The search findingswere examined to determine if temporal
or regional trends could be observed in the publication frequency of studies report-
ing BIA. RESULTS: From 2001 to 2005, a 3.7-fold increase was observed in the
proportion of the literature discussing BIA and from 2006 to 2010, a 3.5-fold in-
crease was observed. When the increasing temporal trend of BIA publication was
examined according to region (limited to Europe and the United States), it was
noted that the trend of an increase in the rate of BIA publication was greater in
Europe than in the USA. CONCLUSIONS: The period of 2001 – 2011 saw an increase
in the number of publications discussing BIA. This trend was more pronounced in
Europe than the US and likely reflects the funding differences of healthcare sys-
tems in these regions, with more limited healthcare budgets typical within Europe
compared to the United States. Future changes to the US health care system, how-
ever, may promote the increased use of BIA in this region.
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OBJECTIVES: To compare two different approaches to estimate the total cost Bo-
livia’s Expanded Program on Immunization (EPI), one using the central budget
reports vs. an alternative approach using a novel ProVac EPI costing Tool.
METHODS: The first approach was applied using cost data from the 2009 budget
approved to the Bolivian Ministry of Heath and regional sources of wage assign-
ments. We estimated the annual cost of Bolivian national EPI following the WHO
recommendations for estimating cost of immunization programs. The second ap-
proach use a new EPI costing tool developed by the PAHO ProVac Initiative and
designed to estimate the costs of every single component of a standard vaccination
program at three administrative levels (district, state, national). A costing survey
was carried out at different vaccination centers. RESULTS: The central level bud-
geting approach resulted in an overall EPI cost of US $11,960,000 for 2009. Using the
EPI costing tool to assess the local and regional costs of vaccination produced an
estimate four times higher, US $53,330,000. The most important items were the
purchase of vaccines and vaccination supplies (46% of the total), followed by per-
sonnelwho contributed about 28%. Cost incurred in the direct delivery of vaccine to
patients were 50% of the total, withmajor participation of personnel and transpor-
tation items. Other cost like vaccination supplies were best defined with this new
approach and also explains the incremental difference. CONCLUSIONS: The cen-
tral Budget cannot be relied on for a full estimation of EPI program costs, it can lose
cost details within the same level. Also, the costs incurred at lower administrative
levels were not well-captured in the central budget and are important of total EPI
costs. The costs of vaccination other than vaccine acquisition and vaccination
supplies are very important and should be considered in cost analysis of vaccine
introduction.
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OBJECTIVES: The purpose of this study is to assess the quality and characteristics
of dossiers submitted to HIRA, focusing on sensitivity analysis. METHODS: Two
researchers independently reviewed the 34 dossiers submitted from January 2007
to Dec. 2009. To analyze how submissions handled uncertainty, we analyzed the
analysis type, assessment items, and ranges of uncertainty and so on. Their adher-
ence to current HIRA’s recommendation was assessed. RESULTS: Thirty out of 34
dossiers performed sensitivity analysis. Deterministic sensitivity analysis, namely,
univariate analysis was most frequently used; probabilistic sensitivity analysis
(PSA) method was applied for only 5 cases and the grounds of the selection of
parameter distributions were rarely provided; 14 cases have provided the grounds
the ranges of uncertainty; 23 cases analyzed utility and effectiveness and 20 cases
analyzed drug cost for assessing uncertainty. Multivariate or threshold analyses
were rarely preformed. CONCLUSIONS: The quality of submitted dossiers in terms
of sensitivity analysis varied greatly. Revised HIRA’s guideline could specify the
minimum standards to reduce variability and increase the comparability of sub-
mitted dossiers.
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OBJECTIVES: The memory-less feature of Markov models can be a limiting factor
when treatment-sequencing needs to be modeled and the transition probability in
second- and subsequent-line treatments are not constant. Tunnel-states are a
common approach to overcome this limitation in cohort models built in excel. As
the number of treatment sequences and time-dependencies increase, however,
tunnel-states can become unruly. We propose an alternative method of nested
Markov modeling to allow time-dependency in treatment sequences. METHODS:
The proposed method first disaggregates the model by treatment and calculates
the costs and benefits for each treatment in the sequence. This effectively gives a
model of each treatment, which can be rolled back in the usual way to give a net
present value (NPV) of the costs and benefits after discounting. The NPVs of each
treatment are then combined into the treatment sequence by weighting propor-
tional to the time spent in the sequence, followed by further discounting to account
for placement in the sequence. This method is tested by building a hypothetical
model with two treatment sequences. i.e. first-line therapy and second-line ther-
apy, followed by a standard-of-care therapy as an absorbing state. Time depen-
dency was modelled by 1) the traditional tunnel state approach, and 2) the pro-
posed nested Markov model approach. RESULTS: Costs and quality-adjusted life-
years gained (discounted to NPV) were $456 and 2.87 for first-line therapy, $915 and
3.34 for second-line and standard-of-care therapy. The two approaches gave iden-
tical NPVs for the treatment sequence of $1296 and 5.94 QALYs. CONCLUSIONS:
Nested Markov modeling represents a straightforward and intuitive approach to
modeling a fixed treatment sequence. It may not be suitable if the position in a
sequence is inter-changeable, and treatment effectiveness depends on the position
in a sequence (e.g. cancer therapies where disease progression impacts treatment
effectiveness).
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OBJECTIVES: To estimate the total costs of the Bolivian Expanded Program of Im-
munization (EPI) from the perspective of the central level of the health system and
to estimate the average cost per fully immunized children (FIC) in the current
Bolivian setting.METHODS:Using cost data from the 2007-2009 budget approved to
the Bolivian MoH (Ministerio de la Salud y el Deporte) and regional sources of wage
assignments, we estimated the annual cost of Bolivian national EPI following the
WHO recommendations for estimating cost of immunization programs. Combin-
ing figures from EPI coverage and costs, cost per FIC were estimated with adjust-
ments for underreporting using secondary data sources. Costs are expressed in
2009 U.S. dollars. RESULTS: In 2007, 2008, and 2009 the Bolivian EPI central level
expended US$11,616,108, US$10,297,322, and US$11,959,509, respectively. The
most important items were vaccines purchasing and acquisition of vaccination
supplies (85% in average for 3 years), followed by personnel who contributed about
8,9% in average to same period. The cost per FIC was between US$ 6 and $93 with
basic scheme, and between $53 and $144 per FIC with basic scheme plus rotavirus.
CONCLUSIONS: This is one of the few studies in LAC attempting to establish the
cost of every single national EPI activity. The cost per child vaccinated in Bolivia is
explainedmainly by the costs of vaccines and personnel costs, however this result
should be considered as a very conservative one due to lack of cost data of inferior
levels of national EPI.
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